HRP20211288T1 - Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati - Google Patents
Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati Download PDFInfo
- Publication number
- HRP20211288T1 HRP20211288T1 HRP20211288TT HRP20211288T HRP20211288T1 HR P20211288 T1 HRP20211288 T1 HR P20211288T1 HR P20211288T T HRP20211288T T HR P20211288TT HR P20211288 T HRP20211288 T HR P20211288T HR P20211288 T1 HRP20211288 T1 HR P20211288T1
- Authority
- HR
- Croatia
- Prior art keywords
- serotype
- capsular polysaccharide
- immunogenic
- immunogenic conjugate
- kda
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims 18
- 229920001282 polysaccharide Polymers 0.000 title claims 18
- 239000005017 polysaccharide Substances 0.000 title claims 18
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims 3
- 230000002163 immunogen Effects 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 239000007800 oxidant agent Substances 0.000 claims 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 230000021615 conjugation Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 229940031348 multivalent vaccine Drugs 0.000 claims 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical group OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Sustainable Development (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (22)
1. Postupak priprave imunogenog konjugata koji sadrži kapsularni polisaharid serotipa 15B bakterije Streptococcus pneumoniae, kovalentno vezan na proteinski nosač, naznačen time što se postupak sastoji u koracima:
(a) vezanja aktiviranog kapsularnog polisaharida serotipa 15B na proteinski nosač, gdje se navedeni aktivirani polisaharid dobiva postupkom koji se sastoji u koracima reakcije izoliranog kapsularnog polisaharida serotipa 15B bakterije Streptococcus pneumoniae, koji sadrži najmanje 0,6 mM acetata po mM navedenog kapsularnog polisaharida serotipa 15B, s oksidirajućim sredstvom, gdje navedeni aktivirani polisaharid ima molekulsku težinu između 100 i 300 kDa; i
(b) reakcije vezanog, aktiviranog polisaharida i proteinskog nosača s reducirajućim sredstvom kako bi se dobilo konjugat kapsularnog polisaharida serotipa 15B s proteinskim nosačem;
gdje se korak (a) i korak (b) provodi u DMSO-u.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je proteinski nosač CRM197.
3. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što je koncentracija aktiviranog kapsularnog polisaharida serotipa 15B u koraku (b) između 0,1 i 10 mg/ml, 0,5 i 5 mg/ml ili 0,5 i 2 mg/ml.
4. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je početni ulazni omjer između aktiviranog kapsularnog polisaharida serotipa 15B i proteinskog nosača između 5:1 i 0,1:1, 2:1 i 0,1:1, 2:1 i 1:1, 1,5:1 i 1:1, 0,1:1 i 1:1, 0,3:1 i 1:1, 0,6:1 i 1:1, ili 0,6:1 i 1,5:1.
5. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što u koraku (b) aktivirani polisaharid reagira s između 1 i 2 molarna ekvivalenta natrijevog cijanoborohidrida u trajanju od 40 do 50 sati na temperaturi između 20 do 26 °C.
6. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što navedeni postupak uključuje dodatni sljedeći korak:
(c) zatvaranja neizreagiranog aldehida dodavanjem NaBH4.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je navedeno oksidirajuće sredstvo perjodat.
8. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je navedeno oksidirajuće sredstvo natrijev perjodat.
9. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je navedeno oksidirajuće sredstvo natrijev metaperjodat.
10. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je prinos u koraku konjugacije (b) veći od 50%.
11. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što navedeni postupak dodatno uključuje korak formuliranja konjugata u polivalentno cjepivo.
12. Imunogeni konjugat, naznačen time što ga se dobiva postupkom u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
13. Imunogeni konjugat u skladu s patentnim zahtjevom 12, naznačen time što navedeni imunogeni konjugat sadrži manje od 40% slobodnog kapsularnog polisaharida serotipa 15B u usporedbi s ukupnom količinom kapsularnog polisaharida serotipa 15B.
14. Imunogeni konjugat u skladu s patentnim zahtjevom 12 ili 13, naznačen time što imunogeni konjugat ima molekulsku težinu između: 3000 i 20000 kDa; 5000 i 10000 kDa; 5000 i 20000 kDa; 8000 i 20000 kDa; 8000 i 16000 kDa; ili 10000 i 16000 kDa.
15. Imunogeni konjugat u skladu s bilo kojim od patentnih zahtjeva 12 do 14, naznačen time što je omjer između kapsularnog polisaharida serotipa 15B i proteinskog nosača u konjugatu između 0.4 i 2.
16. Imunogeni konjugat u skladu s bilo kojim od patentnih zahtjeva 12 do 15, naznačen time što najmanje 40% imunogenog konjugata ima Kd manji ili jednak 0,3 na stupcu CL-4B.
17. Imunogeni konjugat u skladu s bilo kojim od patentnih zahtjeva 12 do 16, naznačen time što je stupanj konjugacije između: 2 i 15; 2 i 13; 2 i 10; 2 i 8; 2 i 6; 2 i 5, 2 i 4; 3 i 15; 3 i 13; 3 i 10; 3 i 8; 3 i 6; 3 i 5; 3 i 4; 5 i 15; 5 an 10; 8 i 15; 8 i 12; 10 i 15; ili 10 i 12.
18. Imunogeni konjugat u skladu s bilo kojim od patentnih zahtjeva 12 do 17, naznačen time što je omjer između mM acetata po mM kapsularnog polisaharida serotipa 15B u imunogenom konjugatu i mM acetata po mM kapsularnog polisaharida serotipa 15B u aktiviranom polisaharidu najmanje 0,6, 0,65, 0,7, 0,75, 0,8, 0,85, 0,9, ili 0,95, po mogućnosti najmanje 0,7 ili najmanje 0,9.
19. Imunogeni pripravak, naznačen time što sadrži imunogeni konjugat u skladu s bilo kojim od patentnih zahtjeva 12 do 18 i fiziološki prihvatljivi vehikulum.
20. Cjepivo, naznačeno time što sadrži imunogeni pripravak u skladu s patentnim zahtjevom 19.
21. Imunogeni pripravak u skladu s patentnim zahtjevom 19, ili cjepivo u skladu s patentnim zahtjevom 20, naznačeni time što su namijenjeni upotrebi u postupku zaštite subjekta od infekcije serotipom 15B bakterije Streptococcus pneumoniae.
22. Imunogeni pripravak u skladu s patentnim zahtjevom 19, ili cjepivo u skladu s patentnim zahtjevom 20, naznačeni time što su namijenjeni upotrebi u postupku liječenja ili sprječavanja infekcije bakterijom Streptococcus pneumoniae, bolesti ili stanja povezanog sa serotipom 15B bakterije Streptococcus pneumoniae kod subjekta, gdje se navedeni postupak sastoji u koraku primjene terapijski ili profilaktički djelotvorne količine imunogenog pripravka ili navedenog cjepiva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929561P | 2014-01-21 | 2014-01-21 | |
| EP15708581.2A EP3096786B1 (en) | 2014-01-21 | 2015-01-15 | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| PCT/IB2015/050316 WO2015110942A2 (en) | 2014-01-21 | 2015-01-15 | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211288T1 true HRP20211288T1 (hr) | 2021-11-26 |
Family
ID=52630421
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231504TT HRP20231504T1 (hr) | 2014-01-21 | 2015-01-15 | Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati |
| HRP20211288TT HRP20211288T1 (hr) | 2014-01-21 | 2021-08-11 | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231504TT HRP20231504T1 (hr) | 2014-01-21 | 2015-01-15 | Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20160324949A1 (hr) |
| EP (3) | EP3096786B1 (hr) |
| JP (3) | JP6585624B2 (hr) |
| KR (4) | KR102619514B1 (hr) |
| CN (2) | CN112336854A (hr) |
| AU (3) | AU2015208822B2 (hr) |
| BR (2) | BR112016016580B1 (hr) |
| CA (1) | CA2937190A1 (hr) |
| DK (2) | DK3583947T3 (hr) |
| ES (2) | ES2883571T3 (hr) |
| FI (1) | FI3583947T3 (hr) |
| FR (1) | FR22C1041I2 (hr) |
| HK (1) | HK1232133A1 (hr) |
| HR (2) | HRP20231504T1 (hr) |
| HU (2) | HUE055553T2 (hr) |
| IL (2) | IL311385A (hr) |
| MX (2) | MX371453B (hr) |
| PL (2) | PL3096786T3 (hr) |
| PT (2) | PT3583947T (hr) |
| RU (2) | RU2688831C2 (hr) |
| SI (2) | SI3096786T1 (hr) |
| WO (1) | WO2015110942A2 (hr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6612260B2 (ja) | 2014-01-21 | 2019-11-27 | ファイザー・インク | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| PE20240927A1 (es) * | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
| IL264553B2 (en) | 2016-08-05 | 2023-04-01 | Sanofi Pasteur Inc | A multivalent pneumococcal protein-polysaccharide conjugate preparation |
| TWI789357B (zh) | 2016-08-05 | 2023-01-11 | 南韓商Ｓｋ生物科技股份有限公司 | 多價肺炎球菌多醣-蛋白質共軛物組成物(二) |
| US11844829B2 (en) | 2016-12-28 | 2023-12-19 | Zalvac Ab | Microparticles from Streptococcus pneumoniae as vaccine antigens |
| CA3048981A1 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| ES2911490T3 (es) * | 2017-01-20 | 2022-05-19 | Pfizer | Composiciones inmunogénicas para su uso en vacunas antineumocócicas |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| CA3052621A1 (en) | 2017-02-03 | 2018-08-09 | Schadeck, Eva Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
| CN110337307A (zh) | 2017-02-24 | 2019-10-15 | 默沙东公司 | 增强肺炎链球菌多糖-蛋白缀合物的免疫原性 |
| WO2018222741A1 (en) * | 2017-05-31 | 2018-12-06 | Oklahoma Medical Research Foundation | Bispecific antibodies for the treatment of streptococcus pneumonia |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| KR102634811B1 (ko) | 2017-06-10 | 2024-02-06 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| CA3074703A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| JP7218358B2 (ja) | 2017-09-07 | 2023-02-06 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
| JP7369123B2 (ja) * | 2017-12-06 | 2023-10-25 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖類－タンパク質コンジュゲートを含む組成物およびその使用方法 |
| US11123417B2 (en) | 2018-02-05 | 2021-09-21 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA3087572A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| AU2019256218A1 (en) | 2018-04-18 | 2020-12-03 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| KR20210005158A (ko) * | 2018-04-30 | 2021-01-13 | 머크 샤프 앤드 돔 코포레이션 | 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법 |
| KR20210002641A (ko) | 2018-04-30 | 2021-01-08 | 머크 샤프 앤드 돔 코포레이션 | 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법 |
| CN112543649A (zh) * | 2018-07-04 | 2021-03-23 | Vaxcyte公司 | 免疫原性缀合物的改进 |
| AU2019341723B2 (en) * | 2018-09-23 | 2024-03-21 | Biological E Limited | Purified capsular polysaccharides of Streptococcus pneumoniae |
| MA54533A (fr) * | 2018-12-19 | 2022-03-30 | Merck Sharp & Dohme | Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation |
| JP7239509B6 (ja) * | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| TW202116352A (zh) * | 2019-07-18 | 2021-05-01 | 南韓商賽特瑞恩股份有限公司 | 包含多價肺炎球菌多醣-蛋白共軛物的免疫組成物、醫藥組成物及其用途 |
| AU2020323498A1 (en) * | 2019-07-31 | 2022-03-03 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| WO2021229604A1 (en) * | 2020-05-14 | 2021-11-18 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
| AU2021373358A1 (en) * | 2020-11-04 | 2023-06-01 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686102A (en) * | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| CA2063271A1 (en) | 1989-07-14 | 1991-01-15 | Subramonia Pillai | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ，ミヒャエル | 油除去装置を備えたエンジン |
| ES2204900T3 (es) | 1992-02-11 | 2004-05-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Estructura inmuinogena de doble vector. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| DE69324487T2 (de) | 1992-05-06 | 1999-08-12 | Harvard College | Rezeptorbindende region des diphtherietoxius |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
| ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| CA2215933C (en) | 1995-03-22 | 2009-10-13 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| US5714354A (en) * | 1995-06-06 | 1998-02-03 | American Home Products Corporation | Alcohol-free pneumococcal polysaccharide purification process |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| BR9914160A (pt) | 1998-09-30 | 2001-06-26 | American Cyanamid Co | Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante |
| EP2050464B1 (en) | 1998-12-21 | 2019-08-07 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| PT2261358E (pt) | 1998-12-23 | 2014-07-30 | Id Biomedical Corp Quebec | Antigénios de streptococcus |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| TR200704553T2 (tr) | 2000-06-20 | 2007-11-21 | Id Biomedical Corporation | Streptokok antijenleri. |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| CN1541111A (zh) | 2001-06-07 | 2004-10-27 | ���Ͽع�����˾ | 作为佐剂的霍乱全毒素的突变形式 |
| EP1404368B1 (en) | 2001-06-07 | 2009-12-09 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| EP1456231A2 (en) | 2001-12-20 | 2004-09-15 | Shire Biochem Inc. | Streptococcus antigens |
| PT1601689E (pt) | 2003-03-13 | 2008-01-04 | Glaxosmithkline Biolog Sa | Processo de purificação para citolisina bacteriana |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| CN102716480B (zh) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| NZ562719A (en) | 2005-04-08 | 2008-12-24 | Wyeth Corp | Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN101378778B (zh) * | 2005-12-22 | 2013-02-06 | 葛兰素史密丝克莱恩生物有限公司 | 肺炎球菌多糖缀合物疫苗 |
| RU2460539C2 (ru) | 2006-10-10 | 2012-09-10 | Вайет | СПОСОБ ОЧИСТКИ ПОЛИСАХАРИДОВ Streptococcus pneumoniae 3 ТИПА (ВАРИАНТЫ) |
| PL2129693T3 (pl) | 2007-03-23 | 2017-07-31 | Wyeth Llc | Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae |
| EP2170391B1 (en) * | 2007-06-20 | 2017-01-18 | Pfizer Ireland Pharmaceuticals | Modified polysaccharides for conjugate vaccines |
| AU2008267208B2 (en) | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| BRPI1014494A2 (pt) | 2009-04-30 | 2016-08-02 | Coley Pharm Group Inc | vacina pneumocócica e usos da mesma |
| US9125951B2 (en) * | 2009-06-22 | 2015-09-08 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| RU2013131795A (ru) * | 2010-12-10 | 2015-01-20 | Мерк Шарп Энд Домэ Корп. | Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций |
| GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| AU2012255878B2 (en) * | 2011-05-18 | 2016-05-12 | Matrivax Research & Development Corporation | Protein matrix vaccine compositions including polycations |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| MX363511B (es) * | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
| HRP20221438T1 (hr) * | 2012-12-20 | 2023-02-03 | Pfizer Inc. | Postupak glikokonjugiranja |
| EP3616716A3 (en) * | 2014-01-21 | 2020-05-06 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20240927A1 (es) * | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
-
2015
- 2015-01-15 SI SI201531683T patent/SI3096786T1/sl unknown
- 2015-01-15 PT PT191795772T patent/PT3583947T/pt unknown
- 2015-01-15 FI FIEP19179577.2T patent/FI3583947T3/fi active
- 2015-01-15 CN CN202011016155.6A patent/CN112336854A/zh active Pending
- 2015-01-15 IL IL311385A patent/IL311385A/en unknown
- 2015-01-15 JP JP2016564448A patent/JP6585624B2/ja active Active
- 2015-01-15 HR HRP20231504TT patent/HRP20231504T1/hr unknown
- 2015-01-15 AU AU2015208822A patent/AU2015208822B2/en active Active
- 2015-01-15 ES ES15708581T patent/ES2883571T3/es active Active
- 2015-01-15 WO PCT/IB2015/050316 patent/WO2015110942A2/en active Application Filing
- 2015-01-15 BR BR112016016580-2A patent/BR112016016580B1/pt active IP Right Grant
- 2015-01-15 RU RU2016127123A patent/RU2688831C2/ru active
- 2015-01-15 MX MX2016009469A patent/MX371453B/es active IP Right Grant
- 2015-01-15 DK DK19179577.2T patent/DK3583947T3/da active
- 2015-01-15 HU HUE15708581A patent/HUE055553T2/hu unknown
- 2015-01-15 KR KR1020227039818A patent/KR102619514B1/ko active IP Right Grant
- 2015-01-15 EP EP15708581.2A patent/EP3096786B1/en active Active
- 2015-01-15 IL IL246738A patent/IL246738B1/en unknown
- 2015-01-15 SI SI201531977T patent/SI3583947T1/sl unknown
- 2015-01-15 ES ES19179577T patent/ES2965616T3/es active Active
- 2015-01-15 PL PL15708581T patent/PL3096786T3/pl unknown
- 2015-01-15 KR KR1020197034425A patent/KR102229568B1/ko active IP Right Grant
- 2015-01-15 EP EP23195316.7A patent/EP4286000A3/en active Pending
- 2015-01-15 PL PL19179577.2T patent/PL3583947T3/pl unknown
- 2015-01-15 PT PT157085812T patent/PT3096786T/pt unknown
- 2015-01-15 CN CN201580005248.XA patent/CN106413747A/zh active Pending
- 2015-01-15 US US15/110,902 patent/US20160324949A1/en not_active Abandoned
- 2015-01-15 MX MX2020001138A patent/MX2020001138A/es unknown
- 2015-01-15 EP EP19179577.2A patent/EP3583947B1/en active Active
- 2015-01-15 RU RU2019114121A patent/RU2743793C1/ru active
- 2015-01-15 DK DK15708581.2T patent/DK3096786T3/da active
- 2015-01-15 KR KR1020217007584A patent/KR20210032013A/ko active Application Filing
- 2015-01-15 BR BR122023022294-6A patent/BR122023022294A2/pt unknown
- 2015-01-15 KR KR1020167022420A patent/KR102049825B1/ko active IP Right Grant
- 2015-01-15 CA CA2937190A patent/CA2937190A1/en active Pending
- 2015-01-15 HU HUE19179577A patent/HUE064837T2/hu unknown
-
2017
- 2017-06-09 HK HK17105722.5A patent/HK1232133A1/zh unknown
-
2018
- 2018-10-22 US US16/166,708 patent/US20190070283A1/en not_active Abandoned
-
2019
- 2019-06-25 JP JP2019117289A patent/JP2019172701A/ja active Pending
-
2020
- 2020-07-06 AU AU2020204508A patent/AU2020204508B2/en active Active
- 2020-12-17 US US17/125,555 patent/US20210121555A1/en active Pending
-
2021
- 2021-04-05 JP JP2021063880A patent/JP7216137B2/ja active Active
- 2021-08-11 HR HRP20211288TT patent/HRP20211288T1/hr unknown
-
2022
- 2022-07-28 FR FR22C1041C patent/FR22C1041I2/fr active Active
-
2023
- 2023-03-14 AU AU2023201579A patent/AU2023201579A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211288T1 (hr) | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati | |
| HRP20211337T1 (hr) | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati | |
| JOP20200141A1 (ar) | تركيبات مشتملة على متقارنات بروتين عديد سكاريد المكورات العقدية الرئوية وطرق استخدامها | |
| HRP20221438T1 (hr) | Postupak glikokonjugiranja | |
| JP2020533437A5 (hr) | ||
| JP2020533438A5 (hr) | ||
| MX2020002558A (es) | Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora. | |
| JP2021505589A5 (hr) | ||
| JP2020533439A5 (hr) | ||
| CR20210333A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso | |
| JP2020533442A5 (hr) | ||
| MX2023001947A (es) | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. | |
| JP2017504661A5 (hr) | ||
| HRP20110685T1 (hr) | Cjepivo od konjugata pneumokoknog polisaharida | |
| PH12017501898A1 (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| JP2017504660A5 (hr) | ||
| JP2013079285A5 (hr) | ||
| WO2009000825A3 (en) | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates | |
| EA200801935A1 (ru) | Конъюгатные вакцины | |
| MX2021014710A (es) | Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo. | |
| JP2023537945A (ja) | 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン | |
| KR102388325B1 (ko) | 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법 | |
| ES2967001T3 (es) | Composiciones inmunogénicas | |
| RU2022129006A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| RU2020112312A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель |